Loading
A phase 2 trial of HER2 PET in Breast cancer and HER2-positive gastric cancer, run by Karolinska University Hospital, with a status the registry has not verified recently.
[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors is a phase 2 interventional study registered as NCT05619016 by Karolinska University Hospital, with 72 participants planned, started 2022-11-23 and due to reach its primary completion in 2025-12-31. Interventions recorded: [68Ga]Ga-ABY-025 PET, Biopsy and analysis of HER2 expression. Conditions recorded: Esophageal Neoplasms, Gastric Neoplasms Malignant, Breast Cancer, HER2-positive Gastric Cancer.
Linked to the technology HER2 PET because the registry names it ("her2 pet") among its interventions and Breast cancer and HER2-positive gastric cancer among its conditions. Registry record only: no result has been read by an editor.
Shares HER2 PET, Breast cancer (all types) and the tag pipeline.
Shares HER2-positive gastric cancer and the tag pipeline.
Shares HER2 PET and the tag pipeline.
Shares HER2-positive gastric cancer and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.